UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

The New England journal of medicine, 2011-06, Vol.364 (22), p.2119-2127

2011

Volltextzugriff (PDF)

Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer

Surgery, 2012-12, Vol.152 (6), p.1078-1087

2012

Volltextzugriff (PDF)

Using a data-driven approach to deliver complex studies in advanced therapeutics

Immuno Oncology Insights, 2023-07, Vol.4 (6), p.171-171

2023

Volltextzugriff (PDF)

Solving challenges in cell therapy clinical trials & effectively delivering complex studies in advanced therapeutics

Immuno Oncology Insights, 2023-04, Vol.4 (2), p.79-87

2023

Volltextzugriff (PDF)

Lymphatic mapping for staging of head and neck cancer

Seminars in oncology, 2004-06, Vol.31 (3), p.382-393

2004

Volltextzugriff (PDF)

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma

Thyroid (New York, N.Y.), 2014-02, Vol.24 (2), p.232-240

2014

Volltextzugriff (PDF)

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

OncoTargets and therapy, 2016, Vol.9, p.7275-7283

2016

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-03, Vol.18 (5), p.1415-1425

2012

Volltextzugriff (PDF)

Abstract A4: Combretastatin A-4 Phosphate (CA4P) is effective for the treatment of functional pancreatic neuroendocrine tumors (PNETs) in a transgenic mouse model

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A4-A4

2013

Volltextzugriff (PDF)

A randomized Phase II trial of the tumor vascular disrupting agent CA4P

OncoTargets and therapy, 2016-01, Vol.9, p.7275

2016

Volltextzugriff (PDF)

Increasing Birth Cohort Screening for Chronic Hepatitis C in a Primary Care Clinic with Panel Management

Journal of community health, 2019-12, Vol.44 (6), p.1055-1060

2019

Volltextzugriff (PDF)

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood, 2012-11, Vol.120 (21), p.4335-4335

2012

Volltextzugriff (PDF)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate

BMC pharmacology & toxicology, 2013-01, Vol.14 (1), p.7-7, Article 7

2013

Volltextzugriff (PDF)

Abstract B19: Interim safety results of a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (Ca4p) with carboplatin, paclitaxel and bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.B19-B19

2009

Volltextzugriff (PDF)

Lymphatic mapping for staging of head and neck cancer: Radioguided surgery

Seminars in oncology, 2004, Vol.31 (3), p.382-393

2004

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(15)

Sprache

Englisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer

Using a data-driven approach to deliver complex studies in advanced therapeutics

Solving challenges in cell therapy clinical trials & effectively delivering complex studies in advanced therapeutics

Lymphatic mapping for staging of head and neck cancer

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

Abstract A4: Combretastatin A-4 Phosphate (CA4P) is effective for the treatment of functional pancreatic neuroendocrine tumors (PNETs) in a transgenic mouse model

A randomized Phase II trial of the tumor vascular disrupting agent CA4P

Increasing Birth Cohort Screening for Chronic Hepatitis C in a Primary Care Clinic with Panel Management

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate

Abstract B19: Interim safety results of a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (Ca4p) with carboplatin, paclitaxel and bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer

Lymphatic mapping for staging of head and neck cancer: Radioguided surgery

Aktive Filter

Suchergebnisse filtern